Wisconsin Tuberculosis (TB) Program Updates

Julie Tans-Kersten
Director, Wisconsin TB Program (WTBP)
Wisconsin Mycobacteriology Laboratory Network Virtual Conference
November 3, 2021
Topics

• Effect of COVID-19 pandemic on TB
• Wisconsin TB Program (WTBP) updates
• New national TB guidelines and resources
• New WTBP materials
Effect of COVID-19 Pandemic on TB

• The COVID-19 pandemic is having a devastating impact on the fight against other deadly infectious diseases such as HIV, TB and malaria.

• Resources were diverted to combat the COVID-19 pandemic.

• Prevention, testing and treatment services for other diseases decreased.
Effect of COVID-19 Pandemic on TB

• In countries the Global Fund supports, the number of individuals tested and treated for TB fell by:
  o 18% for susceptible TB
  o 37% for extensively drug resistant TB

• Approximately one million untreated TB cases will lead to increased transmission and more deaths.
Effect of COVID-19 Pandemic on TB

• The pandemic is the most significant set-back in TB prevention and control in two decades.

• In some countries, the secondary effects on HIV, TB and malaria could exceed the direct impact of COVID-19.
Effect of COVID-19 Pandemic on TB

- Wisconsin: 30% fewer TB cases in 2020
- True decline in TB incidence?
- Under-ascertainment of cases?
Rifamycin Issues: Background

• Rifamycins are important drugs used in regimens for treatment of TB disease and latent TB infection (LTBI).
• There are two interrelated issues:
  o Drug shortage
  o Nitrosamine contamination
Nitrosamine Contamination

• The US Food and Drug Administration (FDA) recently began testing for nitrosamines.
• Nitrosamines are potential carcinogens.
• Nitrosamine impurities were found in rifampin and rifapentine.
• FDA is allowing continued distribution of these medications.
Rifamycin Shortages

- The shortage is attributed to increased global demand and nitrosamine contamination.
- Wisconsin has experienced shortages of rifapentine and rifabutin.
- Wisconsin has not experienced rifampin shortages.
  - Providers should continue prescribing rifampin for treatment of TB disease per existing guidelines.
WTBP Response to Rifamycin Issues

- WTBP will approve further use of rifapentine and rifabutin through the Wisconsin TB Dispensary on a case-by-case basis, depending on the supply of medication.
- The Wisconsin TB Dispensary pharmacy assures the supply of medication for each patient that starts a 3HP regimen.
# New National TB Guidelines

<table>
<thead>
<tr>
<th>Release Date</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/2021</td>
<td>Updated Guidance on Co-Administration of COVID-19 Vaccine and Tuberculin Skin Test (TST) or Interferon Gamma Release Assay (IGRA) blood test. DHS Gov Delivery message: <a href="https://content.govdelivery.com/accounts/WIDHS/bulletins/2ef6ae3">https://content.govdelivery.com/accounts/WIDHS/bulletins/2ef6ae3</a></td>
</tr>
<tr>
<td>05/28/21</td>
<td>NTCA TB Nurse Case Manager Core Competencies: <a href="http://www.tbcontrollers.org/resources/core-competencies/">http://www.tbcontrollers.org/resources/core-competencies/</a></td>
</tr>
</tbody>
</table>
New Study

• Study: shorter regimen for treatment of TB disease

• 4-month regimen containing rifapentine and moxifloxacin

• 4-month regimen containing rifapentine and moxifloxacin was non-inferior to standard 6-month regimen

**NEJM 384; 18. May 6, 2021.**
# New WTBP Materials

<table>
<thead>
<tr>
<th>Publication Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-42027</td>
<td>Non-tuberculous mycobacterial (NTM) infections: Information for providers and local and tribal partners</td>
</tr>
<tr>
<td>P-02969</td>
<td>Home Isolation Agreement</td>
</tr>
<tr>
<td>P-02849</td>
<td>Hospital Discharge Checklist</td>
</tr>
</tbody>
</table>

Acknowledgements

• Wisconsin State Laboratory of Hygiene
• Clinical Laboratories
• Local and Tribal Health Departments
• WTBP Team
WTBP Staff

Tierney Hall
Pat Heger
Claire Leback
Julie Tans-Kersten
Savitri Tsering
Philip Wegner
WTBP Contact Information

Phone: 608-261-6319
Fax: 608-266-0049
Email: dhswitbprogram@dhs.wisconsin.gov

Website:
https://www.dhs.wisconsin.gov/tb/index.htm
Questions?